AzTrials
AzTrials

The Patients Who Receive Percutaneous Endoscopic GastrostomyPEGNCT01237730

Tailored Antibiotics Prophylaxis for Percutaneous Endoscopic Gastrostomy

A study testing cefuroxime and Tailored antibiotic in people with The Patients Who Receive Percutaneous Endoscopic Gastrostomy and Peristomal Wound Infection After the Operation of PEG, run by National Cheng Kung University at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Tailored antibiotic prophylaxis according to the individual throat swab culture could reduce the peristomal infection rate Read more about this study

Who is it for?
Ages 20 to 80 years
What is being tested?
cefuroxime and Tailored antibiotic
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteTaiwan
Study dates
Jul 2010to Aug 2011
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The patients who receive PEG by pull method in our hospital, a tertiary transferring center, will be included

Who cannot join

  • The exclusion criteria for entry are inability to place the gastrostomy for technical reasons, such as oropharyngeal deformity or esophageal stricture. The patients who receive PEG by percutaneous push method will be excluded. The patients will be also excluded if active infection and fever are identified, and the PEG is delayed until the infection is brought under control.

Trial locations and contacts

1 site in 1 country.

chiao-hsiung chuang, M.D. contact

88662353535 ext. 2679

chuang.chiaohsiung@gmail.com

Taiwan1 site, 1 recruiting
  • National Cheng Kung University Hospital

    Tainan, 704

    chiaohsiung chuang, M.D., 88662353535 ext. 2679, chuang.chiaohsiung@gmail.com

    chiao-hsiung chuang, M.D.

    Recruiting

Other trials in Taiwan

About this study

Official title: Impact of Oropharyngeal Microorganism Colonization on the Peristomal Infection After Percutaneous Endoscopic Gastrostomy and the Effect of Tailored Antibiotics Prophylaxis

Tailored antibiotic prophylaxis according to the individual throat swab culture could reduce the peristomal infection rate

Read the detailed description

Past know-how:

Antibiotic prophylaxis has been shown to be effective to reduce peristomal infection.[9-11] The penicillin-or cephalosporin-based antibiotic prophylaxis are usually used with similar efficacy.[12] EuropeanSociety of Gastrointestinal Endoscopy (ESGE) guideline recommend that a single dose of intravenous cephalosporin orpenicillin as preparation before PEG.[17] The updated practice guidelines of American Society for Gastrointestinal Endoscopy (ASGE) and British Society of Gastroenterology (BSG) also recommend cefazolin or cefuroxime as prophylactic antibiotics.[18-19]

Question:

Is the 1st or 2nd generation cephalosporin is adequate as prophylactic antibiotics for percutaneous endoscopic gastrostomy (PEG)?

Preliminary results:

  1. The leading two common pathogen to cause peristomal infection of PEG are P. aeuroginosa and methecillin-resistanced S. aurous. (Figure 1) These two common pathogen can't be covered by the prophylactic antibiotics which suggested by guideline.
  2. The patient with airway infection before PEG had higher peristomal infection rate, comparing with those without airway infection. Moreover, adequate antibiotics prophylaxis could significant improve the infection rate. (Table 1)

Hypothesis:

Tailored antibiotic prophylaxis according to the individual throat swab culture could reduce the peristomal infection rate.

Specific aims:

  1. If individual tailored antibiotic prophylaxis according to throat swab could reduce the peristomal infection rate?
  2. If the phenotype and genotype analysis were compatible between infected wound isolates and throat swab/sputum isolates?
  3. If throat swab culture is better than sputum culture to predict peristomal infected microorganism?
  4. Is the infection is also linked to the oropharyngeal isolates if the patients get peristomal infection more than one week after PEG?

Anticipated results:

  1. Individual tailored antibiotic prophylaxis according to the throat swab culture could reduce the peristomal infection rate of PEG and short the days of hospitalization.
  2. Most phenotype and genotype are compatible between peristomal isolates and throat swab/sputum isolates. It indicates that most pathogens are carried from throat into the peristomal to cause the infection. The microorganism isolated from throat swab could predict the pathogen of PEG peristomal infection.
  3. The throat swab culture may be better than sputum culture to predict the peristomal infected pathogen because some unconscious patients is difficult to collect sputum.
  4. Peristomal infection more than one week after PEG may be not associated to throat pathogen. It may be related to the contamination during wound care.

Significances:

This proposal result could be applied to clinical care of percutaneous endoscopic gastrostomy. The individual chose of prophylactic antibiotics could improve the peristomal infection rate. Currently, 1st or 2nd cephalosporin was usually recommended as prophylaxis before PEG. However, for the patient with ORSA culture from nasal cavity, vancomycin was suggested as prophylaxis because some studies support the benefit on infection prevention. If the results are positive, it may change the clinical guideline on antibiotics prophylaxis before PEG.

Being tested
cefuroxime, Tailored antibiotic
Keywords
percutaneous endoscopic gastrostomy, peristomal wound infection, prophylactic antibiotics

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cefuroximeDrug

    Use the cefuroxime as prophylaxis.

  • Tailored antibioticDrug

    Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.

Study groups in NCT01237730
Study groupRoleWhat they receive
Cefuroxime groupActive comparatorUse the cefuroxime as prophylactic antiobiotics, according to the clinical guideline.
Receives: Drug: cefuroxime
Tailored antibiotics groupExperimentalTailored antibiotic is selected according to the patient's oropharyngeal microorganisms.
Receives: Drug: Tailored antibiotic

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Peristomal wound infection

    Measured: Two weeks after operation of PEG

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Nov 2010 (estimated)
  2. Study startJul 2010
  3. Primary completionJul 2011 (estimated)
  4. Study completionAug 2011 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01237730
Sponsor's protocol ID
NCKU-HR99
Acronym
PEG
Status last verified
Jul 2010
First submitted
9 Nov 2010
Last updated
10 Nov 2010
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing cefuroxime and Tailored antibiotic in people with The Patients Who Receive Percutaneous Endoscopic Gastrostomy and Peristomal Wound Infection After the Operation of PEG, run by National Cheng Kung University at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Nov 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact chiao-hsiung chuang, M.D. (88662353535 ext. 2679, chuang.chiaohsiung@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Peristomal wound infection (time frame: Two weeks after operation of PEG). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in